Smoking and the risks of adult diseases

October 2018
Laura Webster
Colin Angus
Alan Brennan
Duncan Gillespie

Address for correspondence:
Dr Duncan Gillespie
School of Health and Related Research
University of Sheffield
Regent Court
Regent Street
Sheffield
S1 4DA
UK
Mail: duncan.gillespie@sheffield.ac.uk

Acknowledgements

Introduction

This document presents our list of **52** adult diseases related to smoking and the corresponding relative risks of disease due to smoking, explaining our choices of disease definitions and risk sources. Figure 1 shows the variation in disease-specific risks. We focus on the risks of current smoking and limit ourselves to diseases that affect the consumer themselves e.g. excluding secondary effects of smoking on children. We assume the equivalence of relative risks and odds ratios. Our starting point was the Royal College of Physician's (RCP) report "Hiding in plain sight: Treating tobacco dependency in the NHS" [1], which reviewed smoking–disease associations to produce an updated list of diseases that are caused by smoking and updated risk sources. We mainly keep to the RCP report's disease list, with any deviations from the RCP list and risk sources being for one of two reasons:

1) There are often slightly conflicting ICD-10 code definitions used for some conditions and we have sought to harmonise these consistently across both tobacco and alcohol, based on the Sheffield Alcohol Policy Model (SAPM) v4.0 disease list [2];

2) Since publication of the RCP report, Cancer Research UK (CRUK) produced their own disease list and risk sources for cancers attributable to modifiable risk factors, including tobacco and alcohol [3]. Discussions with CRUK shaped the disease definitions in our updated Sheffield disease list for alcohol. Where there are differences in the risk sources used in the RCP report and CRUK's work, we take the estimate that matches most closely to our disease definitions, or the more recent estimate.

Tobacco–Alcohol interactions in disease risk

There is limited evidence for the risk of disease in someone who consumes both tobacco and alcohol (RR_{ta}) being higher than would be expected from combining the independent risks from tobacco (RR_t) and alcohol (RR_a). This additional risk due to tobacco-alcohol interaction (over and above the combination of the independent contributions to risk from tobacco and alcohol) can be expressed as a 'synergy factor' (1) [4, 5].

$$SF = \frac{RR_{ta}}{(RR_t-1)+(RR_a-1)} \qquad\qquad (1)$$

We conducted a scoping review across all diseases for which tobacco and alcohol are causal factors to ascertain the extent of evidence on interaction effects. We include only interactions with a meta-analysis of effect size. The only diseases for which we have found suitable meta-analyses to inform the tobacco–alcohol interaction in risk are cancers of the oral cavity, pharynx, larynx and oesophagus. To evaluate the interaction between tobacco and alcohol and the risk of cancer of the oral cavity, pharynx and larynx, Hashibe et al. [5] conducted a pooled analysis within the INHANCE consortium. For the oral cavity and pharynx, the SF was estimated to be 3.09 (CI 1.82–5.23) i.e. smoking and drinking together causes around a 3-fold increase in the risk of head and neck cancers over and about the independent contributions of tobacco and alcohol. For cancer of the larynx, Hashibe et al.[5] estimate the SF to be 1.62 (CI 0.85–3.09). For cancer of the oesophagus, Prabhu et al. [4] estimated the increase in risk of Squamous Cell Carcinoma in people who both smoke and drink to be characterised by a synergy factor of 1.85 (CI 1.45–2.38).

Figure 1. Relative risks and 95% confidence intervals in current smokers for 52 conditions attributable to smoking.

Cancers

We include all cancers attributable to tobacco as mentioned by CRUK [3], except ovarian cancer. Smoking only carries a risk for fully malignant mucinous ovarian cancers (13% of ovarian cancers are mucinous, and of these 57% are fully malignant). We excluded ovarian cancer due to the uncertainty involved in identifying the cases attributable to smoking based on the ICD-10 definitions used in our mortality data and hospital episode statistics.

Below we itemise each cancer type and explain how we have synthesised the definitions of cancers and the sources for the relative risk of smoking among the Sheffield alcohol disease list [2], RCP report [1], and CRUK's paper [3].

Oral cavity (C00–C06), and pharyngeal (C09, C10, C12–C14)

Gandini et al. [6] estimated the relative risk of smoking for cancer in the oral cavity as 3.43 (95% Confidence Interval 2.37–4.94), and pharyngeal cancers as 6.76 (CI 2.86–16.0). Following Gandini, the RCP report associated the relative risk from Gandini for oral cavity (RR 3.43) with ICD10 code C10, and relative risk for pharyngeal cancer (RR 6.76) with ICD10 code C14. But in line with CRUK, we instead use the risk that Gandini associated with oral cavity cancer (RR 3.43) for pharyngeal cancers with ICD10 codes C09, C10, C12–C14. For oral cavity, we use the risk from Maasland et al. [7] of 1.91 (CI 1.06–3.42) with ICD10 codes C00–C06.

Oesophageal (C15)

Gandini et al. [6] estimated the relative risks of smoking for cancer of the oesophagus as 2.50 (CI 2.00–3.13). Differing from the RCP report but in-line with CRUK, we split oesophageal cancer into its two main histological types: Squamous Cell Carcinoma (SCC) and Adenocarcinoma (AC). CRUK use different relative risks of smoking for each subtype: following CRUK, for SCC, we use the risk from Prabhu et al. [8] of 4.21 (CI 3.13–5.66); for AC, we use the risk from Tramacere et al. [9] of 2.32 (CI 1.96–2.75). We apportion overall oesophageal cancer prevalence between AC and SCC using data on percentage prevalence by age and sex from cancer registries, supplied to us by CRUK.

Colorectal (C18–C20)

The RCP report used the CHANCES consortium [10] estimate of the relative risk of smoking for colorectal cancer of 1.20 (CI 1.07–1.34). CRUK instead use the estimates of Cheng et al. [11], who produce two separate risks of smoking for cancer of the colon and rectum (RR 1.11, 1.44). To align with the SAPM disease list, we define colorectal cancer as a single disease and use the CHANCES risk estimate in-line with the RCP report.

Liver (C22)

The RCP report used Lee et al.'s [12] estimate of the risk of smoking for liver cancer of 1.51 (CI 1.37–1.67). CRUK use the same source but take the sex-specific effects: 1.61 (CI 1.38–1.89) for males and 1.86 (CI 1.33–2.60) for females. Due to the substantial overlap between the sex-specific confidence intervals, we use the overall estimate.

Pancreatic (C25)

CRUK used Bosetti et al.'s [13] estimate from the PanC4 study that the risk of smoking for pancreatic cancer is 2.20 (CI 1.71–2.83). The RCP report used the CHANCES consortium [10] estimate of 1.90 (CI 1.48–2.43), and we use this more recent estimate.

Laryngeal (C32)

The RCP report used Gandini et al.'s [6] estimate for the relative risks of smoking for cancer of the larynx of 6.98 (CI 3.14–15.52). CRUK used the more recent estimate by Zuo et al. [14] of 7.01 (CI 5.56–8.85). We use the estimate of Zuo.

Stomach (C16)

CRUK used the estimate of Ladeiras-Lopes et al. [15] that put the relative risk of stomach cancer among smokers at 1.62 (CI 1.50–1.75) for males and 1.20 (CI 1.01–1.43) for females. The RCP report used the CHANCES consortium [10] estimate of 1.74 (CI 1.50–2.02), and estimates from Gandini et al. [6] are similar. We use the CHANCES estimate.

Lung (C33–C34)

CRUK used Gandini et al.'s [6] estimate of the relative risk of lung cancer among smokers of 8.96 (CI 6.73–12.11). The RCP report used the more recent 2016 meta-analysis by Jayes et al. [16] estimates the risk to be 10.92 (CI 8.28–14.40). We use the Jayes estimate.

Cervical (C53)

Both CRUK and the RCP report use Gandini et al.'s [6] estimate of the relative risk of cervix cancer among smokers of 1.83 (CI 1.51–2.21).

Kidney (C64)

The RCP report used Gandini et al.'s [6] estimate of the relative risk of kidney cancer among smokers of 1.52 (CI 1.33–1.74). CRUK use the more recent meta-analysis by Cumberbatch et al. [17] of 1.35 (CI 1.13–1.60) but associate this with ICD10 codes C64–C66, C68. We use the Cumberbatch estimate for C64.

Lower urinary tract (C65–C66)

In-line with the RCP report, we use Gandini et al.'s [6] estimate of the relative risk of lower urinary tract (renal pelvis, bladder and ureter) cancer of 2.77 (CI 2.17–3.54).

Bladder (C67)

The RCP report used the estimate by van Osch et al. [18] for the risk of bladder cancer among smokers of 3.14 (CI 2.53–3.75). CRUK used the same source but took the sex-specific estimates of 3.44 (CI 2.67–4.22) for males, and 3.56 (CI 2.76–4.36) for females. We use the overall estimate.

Acute myeloid leukaemia (C92)

CRUK used Fircanis et al.'s [19] estimate of the relative risk of acute myeloid leukaemia among smokers of 1.47 (CI 1.08–1.98) but associate it with ICD10 codes C90–C95. The RCP report used the more recent meta-analysis by Colamesta et al. [20], which produced a similar estimate of 1.36 (CI 1.11–1.66). In-line with the RCP report, we use the Colamesta estimate and associate it with ICD10 code C92.

Nasal-sinuses and nasopharynx (C11, C30–C31)

The RCP report and CRUK both used Gandini et al.'s [6] estimate of the relative risk of smoking for nasopharyngeal (C11) and sino-nasal (C30, C31) cancers of 1.95 (CI 1.31–2.91).

Table 1. Relative risks for current vs. never smoking for 16 cancer types.

Grouping	Cancer	ICD10 code	Relative risk	Reference
Lung	Lung	C33–C34	10.92 (8.28–14.40)	Jayes et al (2016) [16]
Head and neck	Nasal sinus and nasopharyngeal	C11, C30–C31	1.95 (1.31–2.91)	Gandini et al (2008) [6]
Head and neck	Oral cavity	C00–C06	1.91 (1.06–3.42)	Maasland et al.(2014) [7]
Head and neck	Pharyngeal	C09, C10, C12–C14	3.43 (2.37–4.94)	Gandini et al (2008) [6]
Head and neck	Laryngeal	C32	7.01 (5.56–8.85)	Zuo et al. (2017) [14]
Gastrointestinal	Oesophageal SCC	C15*	4.21 (3.13–5.66)	Prabhu et al. (2013) [8]
Gastrointestinal	Oesophageal AC	C15*	2.32 (1.96–2.75)	Tramacere et al. (2011) [9]
Gastrointestinal	Stomach	C16	1.74 (1.50–2.02)	Ordóñez-Mena et al (2016) [10]
Gastrointestinal	Pancreatic	C25	1.90 (1.48–2.43)	Ordóñez-Mena et al (2016) [10]
Gastrointestinal	Liver	C22	1.51 (1.37–1.67)	Lee et al (2009) [12]
Gastrointestinal	Colorectal	C18–C20	1.20 (1.07–1.34)	Ordóñez-Mena et al. (2016)
Urinary system	Kidney	C64	1.35 (1.13–1.60)	Cumberbatch et al. (2016) [17]
Urinary system	Lower urinary tract	C65–C66	2.77 (2.17–3.54)	Gandini et al (2008) [6]
Urinary system	Bladder	C67	3.14 (2.53–3.75)	van Osch et al (2016) [18]
Cervical	Cervical	C53	1.83 (1.51–2.21)	Gandini et al (2008) [6]
Blood and bone marrow	Acute Myeloid Leukaemia	C92	1.36 (1.11–1.66)	Colamesta et al (2016) [20]

* we split total oesophageal cancer into two subtype using ratios provided by CRUK

Cardiovascular conditions

Our cardiovascular disease list and risk sources are all in-line with the RCP report, which discusses the sources available. To align with the Sheffield alcohol disease list, we split stroke into haemorrhagic (I60–I62) and ischaemic (I63–I67) but use the same smoking risk for each.

Table 2. Relative risks for current vs. never smoking for 6 cardiovascular conditions.

Disease	ICD10 code	Relative risk	Reference
Ischaemic heart disease	I20–I25	Male 35–64: 3.18 (2.34–4.33) Male 65+: 1.96 (1.62–2.37) Female 35–64: 3.93 (2.56–6.05) Female 65+: 1.95 (1.60–2.37)	Rostron (2013) [21]
Haemorrhagic stroke	I60–I62	Male: 1.57 (1.49–1.88) Female: 1.83 (1.58–2.12)	Peters et al (2013) [22]
Ischaemic stroke	I63–I67	Male: 1.57 (1.49–1.88) Female: 1.83 (1.58–2.12)	Peters et al (2013) [22]
Peripheral arterial disease	I73.9	2.71 (2.28–3.21)	Lu et al (2014) [23]
Abdominal aortic aneurysm	I71	2.41 (1.94–3.01)	Cornuz et al (2004) [24]
Venous thromboembolism	I26, I80–I82	1.23 (1.14–1.33)	Cheng et al (2013) [25]

Respiratory conditions

Our respiratory disease list and risk sources are all in-line with the RCP report. We expand the definition of 'Lower respiratory tract infections' (J09-J18) from the Sheffield alcohol disease list to accommodate the different risks of smoking that the RCP report identified for pneumonia (J12-J18), Influenza – clinically diagnosed (J11), and Influenza – microbiologically confirmed (J09, J10).

Table 3. Relative risks for current vs. never smoking for 8 respiratory conditions.

Grouping	Disease	ICD10 code	Relative risk	Reference
Chronic Obstructive Pulmonary Disease (COPD)	Chronic Obstructive Pulmonary Disease (COPD)	J40–44, J47	4.01 (3.18–5.05)	Jayes et al (2016) [16]
Asthma	Asthma	J45–J46	1.61 (1.07–2.42)	Jayes et al (2016) [16]
Tuberculosis	Tuberculosis	A15–A19	1.57 (1.18–2.10)	Jayes et al (2016) [16]
Lower respiratory tract infections	Pneumonia	J12–J18	2.18 (1.69–2.80)	RCP report (2018) [1]
Lower respiratory tract infections	Influenza – clinically diagnosed	J11	1.34 (1.13–1.59)	RCP report (2018) [1]
Lower respiratory tract infections	Influenza – microbiologically confirmed	J09, J10	5.69 (2.79–11.60)	RCP report (2018) [1]
Idiopathic Pulmonary fibrosis	Idiopathic Pulmonary fibrosis	J84.1	1.58 (1.27–1.97)	Taskar et al (2006) [26]
Obstructive sleep apnoea	Obstructive sleep apnoea	G47.3	1.97 (1.02–3.82)	Jayes et al (2016) [16]

Mental health

Our mental health disease list and risk sources are all in-line with the RCP report.

Table 4. Relative risks for current vs. never smoking for 7 mental health conditions.

Disease	ICD10 code	Relative risk	Reference
Alzheimer's disease	G30	1.40 (1.13–1.73)	Zhong et al (2015) [27]
Vascular dementia	F01	1.38 (1.15–1.66)	Zhong et al (2015) [27]
All-cause dementia	F02, F03	1.30 (1.18–1.45)	Zhong et al (2015) [27]
Depression	F32, F33	1.62 (1.10–2.40)	Luger et al (2014) [28]
Psychosis	F28, F29	2.18 (1.23–3.85)	Gurillo et al (2015) [29]
Schizophrenia	F20–F25	2.24 (1.10–4.55)	RCP report (2018) [1]
Bulimia	F50.2	2.32 (1.12–4.78)	Solmi et al (2016) [30]

Other adult diseases

We include 13 further diseases in-line with the RCP report.

Table 5. Relative risks for current vs. never smoking for 13 other adult diseases.

Disease	ICD10 code	Relative risk	Reference
Rheumatoid arthritis	M05–M06	2.02 (1.75–2.33)	Di Giuseppe et al (2014) [31]
Chronic Kidney Disease	N18 (excluding N18.5)	1.34 (1.23–1.47)	Xia et al (2017) [32]
End-stage renal disease	N18.5	1.91 (1.39–2.64)	Xia et al (2017) [32]
Systemic Lupus Erythematosis	M32	1.56 (1.26–1.95)	Jiang et al (2015) [33]
Diabetes (type 2)	E11	1.37 (1.33–1.42)	Pan et al (2015) [34]
Psoriasis	L40	1.78 (1.52–2.06)	Armstrong et al (2014) [35]
Multiple sclerosis	G35	1.55 (1.48–1.62)	Zhang et al (2015) [36]
Senile cataract	H25	1.47 (1.36–1.59)	Ye et al (2012) [37]
Age-related macular degeneration	H35.3–H52.4	1.86 (1.27–2.73)	Chakravarthy et al (2010) [38]
Low back pain	M54	1.16 (1.02–1.32)	Shiri et al (2010) [39]
Crohn's disease	K50	1.76 (1.40–2.22)	Mahid et al (2006) [40]
Hip fracture in women	S72.0–S72.2	1.30 (1.16–1.45)	Shen et al (2015) [41]
Hearing loss	H90, H91	1.97 (1.44–2.70)	Nomura et al. (2005) [42]

Conditions less common among smokers

We include 2 diseases in-line with the RCP report.

Table 6. Relative risks for current vs. never smoking for 2 conditions less common among smokers.

Disease	ICD10 code	Relative risk	Reference
Ulcerative colitis	K51	0.55 (0.33–0.91)	Dias et al (2015) [43]
Parkinson's disease	G20	0.46 (0.42–0.51)	Breckenridge et al (2016) [44]

Decline in risk over time after quitting smoking

To estimate the risk of disease for former smokers we used the findings of Kontis et al. [45], who re-analysed the change in risk after smoking in the ACS-CPS II study from Oza et al.[46], producing three functions to describe the decline in risk after quitting for each of cancers, CVD and COPD (Figure 2). The estimates were informed by data on former smokers with known quit dates who were disease-free at baseline. The results show the proportion of excess relative risk remaining at each time-point since cessation. A cross-check showed that the figures for cancers were broadly consistent with the findings of the International Agency for Research on Cancer's (IARC) 2007 review of the decline in risk after quitting smoking [47].

The remaining question is how risk declines after quitting smoking for diseases that are not cancers, CVD or COPD. Kontis et al. [45] state that "Randomised trials also indicate that the benefits of behaviour change and pharmacological treatment on diabetes risk occur within a few years, more similar to the CVDs than cancers.[48] Therefore, we used the CVD curve for diabetes." In-line with Kontis, we apply the rate of decline in risk of CVD after quitting smoking to type 2 diabetes. For other diseases, we assume that the relative risk reverts to 1 immediately after quitting i.e. an immediate rather than a gradual decline in risk.

Figure 2. The proportion of remaining risk after quitting. Data from a re-analysis of ACS-CPS II data [45, 46].

References

1.   Hiding in plain sight: treating tobacco dependency in the NHS. London: RCP, 2018 Royal College of Physicians. 2018.

2.   Angus C, Henney M, Webster L, Gillespie D. Alcohol-attributable diseases and dose-response curves for the Sheffield Alcohol Policy Model version 4.02018.

3.   Brown KF, Rumgay H, Dunlop C, Ryan M, Quartly F, Cox A, et al. The fraction of cancer attributable to modifiable risk factors in England, Wales, Scotland, Northern Ireland, and the United Kingdom in 2015. British Journal of Cancer. 2018;118(8):1130-41. doi: 10.1038/s41416-018-0029-6.

4.   Prabhu A, Obi KO, Rubenstein JH. The Synergistic Effects of Alcohol and Tobacco Consumption on the Risk of Esophageal Squamous Cell Carcinoma: A Meta-Analysis. American Journal of Gastroenterology. 2014;109(6):821-7. doi: 10.1038/ajg.2014.71. PubMed PMID: WOS:000344458900006.

5.   Hashibe M, Brennan P, Chuang SC, Boccia S, Castellsague X, Chen C, et al. Interaction between Tobacco and Alcohol Use and the Risk of Head and Neck Cancer: Pooled Analysis in the International Head and Neck Cancer Epidemiology Consortium. Cancer Epidemiology Biomarkers & Prevention. 2009;18(2):541-50. doi: 10.1158/1055-9965.epi-08-0347. PubMed PMID: WOS:000263547800022.

6.   Gandini S, Botteri E, Iodice S, Boniol M, Lowenfels AB, Maisonneuve P, et al. Tobacco smoking and cancer: A meta-analysis. International journal of cancer. 2008;122(1):155-64.

7.   Maasland DH, van den Brandt PA, Kremer B, Goldbohm RAS, Schouten LJ. Alcohol consumption, cigarette smoking and the risk of subtypes of head-neck cancer: results from the Netherlands Cohort Study. BMC cancer. 2014;14(1):187.

8.   Prabhu A, Obi K, Rubenstein J. Systematic review with meta-analysis: race-specific effects of alcohol and tobacco on the risk of oesophageal squamous cell carcinoma. Alimentary pharmacology & therapeutics. 2013;38(10):1145-55.

9.   Tramacere I, La Vecchia C, Negri E. Brief Report: Tobacco Smoking and Esophageal and Gastric Cardia Adenocarcinoma: A Meta-analysis. Epidemiology. 2011:344-9.

10.   Ordóñez-Mena JM, Schöttker B, Mons U, Jenab M, Freisling H, Bueno-de-Mesquita B, et al. Quantification of the smoking-associated cancer risk with rate advancement periods: meta-analysis of individual participant data from cohorts of the CHANCES consortium. BMC medicine. 2016;14(1):62.

11.   Cheng J, Chen Y, Wang X, Wang J, Yan Z, Gong G, et al. Meta-analysis of prospective cohort studies of cigarette smoking and the incidence of colon and rectal cancers. European Journal of Cancer Prevention. 2015;24(1):6-15.

12.   Lee Y-CA, Cohet C, Yang Y-C, Stayner L, Hashibe M, Straif K. Meta-analysis of epidemiologic studies on cigarette smoking and liver cancer. International journal of epidemiology. 2009;38(6):1497-511.

13.   Bosetti C, Lucenteforte E, Silverman D, Petersen G, Bracci P, Ji B, et al. Cigarette smoking and pancreatic cancer: an analysis from the International Pancreatic Cancer Case-Control Consortium (Panc4). Annals of oncology. 2011;23(7):1880-8.

14.   Zuo J-J, Tao Z-Z, Chen C, Hu Z-W, Xu Y-X, Zheng A-Y, et al. Characteristics of cigarette smoking without alcohol consumption and laryngeal cancer: overall and time-risk relation. A meta-analysis of observational studies. European Archives of Oto-Rhino-Laryngology. 2017;274(3):1617-31.

15.   Ladeiras-Lopes R, Pereira AK, Nogueira A, Pinheiro-Torres T, Pinto I, Santos-Pereira R, et al. Smoking and gastric cancer: systematic review and meta-analysis of cohort studies. Cancer causes & control. 2008;19(7):689-701.

16.   Jayes L, Haslam PL, Gratziou CG, Powell P, Britton J, Vardavas C, et al. SmokeHaz: systematic reviews and meta-analyses of the effects of smoking on respiratory health. CHEST Journal. 2016;150(1):164-79.

17.   Cumberbatch MG, Rota M, Catto JW, La Vecchia C. The role of tobacco smoke in bladder and kidney carcinogenesis: a comparison of exposures and meta-analysis of incidence and mortality risks. European urology. 2016;70(3):458-66.

18.   van Osch FH, Jochems SH, van Schooten F-J, Bryan RT, Zeegers MP. Quantified relations between exposure to tobacco smoking and bladder cancer risk: a meta-analysis of 89 observational studies. International journal of epidemiology. 2016;45(3):857-70.

19.   Fircanis S, Merriam P, Khan N, Castillo JJ. The relation between cigarette smoking and risk of acute myeloid leukemia: An updated meta-analysis of epidemiological studies. American journal of hematology. 2014;89(8):E125-E32.

20.   Colamesta V, D'Aguanno S, Breccia M, Bruffa S, Cartoni C, La Torre G. Do the smoking intensity and duration, the years since quitting, the methodological quality and the year of publication of the studies affect the results of the meta-analysis on cigarette smoking and Acute Myeloid Leukemia (AML) in adults? Critical reviews in oncology/hematology. 2016;99:376-88.

21.   Rostron B. Smoking-attributable mortality by cause in the United States: revising the CDC's data and estimates. Nicotine & Tobacco Research. 2012;15(1):238-46.

22.   Peters SA, Huxley RR, Woodward M. Smoking as a risk factor for stroke in women compared with men: A systematic review and meta-analysis of 81 cohorts, including 3 980 359 individuals and 42 401 strokes. Stroke. 2013;44(10):2821-8.

23.   Lu L, Mackay D, Pell J. Meta-analysis of the association between cigarette smoking and peripheral arterial disease. Heart. 2014;100(5):414-23.

24.   Cornuz J, Sidoti Pinto C, Tevaearai H, Egger M. Risk factors for asymptomatic abdominal aortic aneurysm: systematic review and meta-analysis of population-based screening studies. The European Journal of Public Health. 2004;14(4):343-9.

25.   Cheng Y-J, Liu Z-H, Yao F-J, Zeng W-T, Zheng D-D, Dong Y-G, et al. Current and former smoking and risk for venous thromboembolism: a systematic review and meta-analysis. PLoS medicine. 2013;10(9):e1001515.

26.   Taskar VS, Coultas DB. Is Idiopathic Pulmonary Fibrosis an Environmental Disease? Proceedings of the American Thoracic Society. 2006;3(4):293-8.

27.   Zhong G, Wang Y, Zhang Y, Guo JJ, Zhao Y. Smoking is associated with an increased risk of dementia: a meta-analysis of prospective cohort studies with investigation of potential effect modifiers. PLoS One. 2015;10(3):e0118333.

28.   Luger TM, Suls J, Vander Weg MW. How robust is the association between smoking and depression in adults? A meta-analysis using linear mixed-effects models. Addictive Behaviors. 2014;39(10):1418-29. doi: http://doi.org/10.1016/j.addbeh.2014.05.011.

29.   Gurillo P, Jauhar S, Murray RM, MacCabe JH. Does tobacco use cause psychosis? Systematic review and meta-analysis. The Lancet Psychiatry. 2015;2(8):718-25. doi: 10.1016/S2215-0366(15)00152-2.

30.   Solmi M, Veronese N, Sergi G, Luchini C, Favaro A, Santonastaso P, et al. The association between smoking prevalence and eating disorders: a systematic review and meta-analysis. Addiction. 2016;111(11):1914-22. doi: 10.1111/add.13457.

31.   Di Giuseppe D, Discacciati A, Orsini N, Wolk A. Cigarette smoking and risk of rheumatoid arthritis: a dose-response meta-analysis. Arthritis research & therapy. 2014;16(2):R61. Epub 2014/03/07. doi: 10.1186/ar4498. PubMed PMID: 24594022; PubMed Central PMCID: PMCPMC4060378.

32.   Xia J, Wang L, Ma Z, Zhong L, Wang Y, Gao Y, et al. Cigarette smoking and chronic kidney disease in the general population: a systematic review and meta-analysis of prospective cohort studies. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2017;32(3):475-87. Epub 2017/03/25. doi: 10.1093/ndt/gfw452. PubMed PMID: 28339863.

33.   Jiang F, Li S, Jia C. Smoking and the risk of systemic lupus erythematosus: an updated systematic review and cumulative meta-analysis. Clinical rheumatology. 2015;34(11):1885-92. Epub 2015/07/21. doi: 10.1007/s10067-015-3008-9. PubMed PMID: 26188616.

34.   Pan A, Wang Y, Talaei M, Hu FB, Wu T. Relation of active, passive, and quitting smoking with incident type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol.

2015;3(12):958-67. Epub 2015/09/22. doi: 10.1016/s2213-8587(15)00316-2. PubMed PMID: 26388413; PubMed Central PMCID: PMCPMC4656094.

35.   Armstrong AW, Harskamp CT, Dhillon JS, Armstrong EJ. Psoriasis and smoking: a systematic review and meta-analysis. The British journal of dermatology. 2014;170(2):304-14. Epub 2013/10/15. doi: 10.1111/bjd.12670. PubMed PMID: 24117435.

36.   Zhang P, Wang R, Li Z, Wang Y, Gao C, Lv X, et al. The risk of smoking on multiple sclerosis: a meta-analysis based on 20,626 cases from case-control and cohort studies. PeerJ. 2016;4:e1797. Epub 2016/03/26. doi: 10.7717/peerj.1797. PubMed PMID: 27014514; PubMed Central PMCID: PMCPMC4806598.

37.   Ye J, He J, Wang C, Wu H, Shi X, Zhang H, et al. Smoking and risk of age-related cataract: a meta-analysis. Investigative ophthalmology & visual science. 2012;53(7):3885-95. Epub 2012/05/19. doi: 10.1167/iovs.12-9820. PubMed PMID: 22599585.

38.   Chakravarthy U, Wong TY, Fletcher A, Piault E, Evans C, Zlateva G, et al. Clinical risk factors for age-related macular degeneration: a systematic review and meta-analysis. BMC ophthalmology. 2010;10:31. Epub 2010/12/15. doi: 10.1186/1471-2415-10-31. PubMed PMID: 21144031; PubMed Central PMCID: PMCPMC3009619.

39.   Shiri R, Karppinen J, Leino-Arjas P, Solovieva S, Viikari-Juntura E. The Association between Smoking and Low Back Pain: A Meta-analysis. The American Journal of Medicine. 2010;123(1):87.e7-.e35. doi: 10.1016/j.amjmed.2009.05.028.

40.   Mahid SS, Minor KS, Soto RE, Hornung CA, Galandiuk S. Smoking and inflammatory bowel disease: a meta-analysis. Mayo Clin Proc. 2006;81(11):1462-71. Epub 2006/11/24. doi: 10.4065/81.11.1462. PubMed PMID: 17120402.

41.   Shen GS, Li Y, Zhao G, Zhou HB, Xie ZG, Xu W, et al. Cigarette smoking and risk of hip fracture in women: a meta-analysis of prospective cohort studies. Injury. 2015;46(7):1333-40.

42.   Nomura K, Nakao M, Morimoto T. Effect of smoking on hearing loss: quality assessment and meta-analysis. Preventive Medicine. 2005;40(2):138-44.

43.   Dias CC, Rodrigues PP, da Costa-Pereira A, Magro F. Clinical predictors of colectomy in patients with ulcerative colitis: systematic review and meta-analysis of cohort studies. Journal of Crohn's & colitis. 2015;9(2):156-63. Epub 2014/12/18. doi: 10.1093/ecco-jcc/jju016. PubMed PMID: 25518058.

44.   Breckenridge CB, Berry C, Chang ET, Sielken RL, Jr., Mandel JS. Association between Parkinson's Disease and Cigarette Smoking, Rural Living, Well-Water Consumption, Farming and Pesticide Use: Systematic Review and Meta-Analysis. PLOS ONE. 2016;11(4):e0151841. doi: 10.1371/journal.pone.0151841.

45.   Kontis V, Mathers CD, Rehm J, Stevens GA, Shield KD, Bonita R, et al. Contribution of six risk factors to achieving the 25× 25 non-communicable disease mortality reduction target: a modelling study. The Lancet. 2014;384(9941):427-37.

46.   Oza S, Thun MJ, Henley SJ, Lopez AD, Ezzati M. How many deaths are attributable to smoking in the United States? Comparison of methods for estimating smoking-attributable mortality when smoking prevalence changes. Preventive medicine. 2011;52(6):428-33.

47.   International Agency for Research on Cancer, World Health Organization. Reversal of risk after quitting smoking. 2007.

48.   Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. The New England journal of medicine. 2002;346(6):393-403.